Horizon Pharma (HZNP) Reports In-Line Q1 EPS; Lifts FY15 Revenue Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil, producer inflation weaken
- Oil falls on weaker demand outlook and higher US stocks
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Guggenheim Reiterates Buy on Horizon Pharma (HZNP), Lifts PT Following Q1
May 8, 2015 11:48 AM EDTGuggenheim Securities reiterate their Buy rating on Horizon Pharma, Inc, (NASDAQ: HZNP), and raised the target price to $40 (from $35), following Q1 results an increased guidance for 2015. HZNP reported Cash & equivalents of $544.2MM in Q1. HZNP also reported an adjusted diluted EPS of $0.21, in line with... More
